AI Engines For more Details: Perplexity Kagi Labs You
Cognitive Enhancement: Meclofenoxate is classified as a nootropic or "smart drug" due to its purported ability to enhance cognitive function. It is believed to improve memory, concentration, and learning abilities, though the exact mechanism of action is not fully understood.
Cholinergic Activity: Meclofenoxate is thought to exert its effects by increasing the levels of acetylcholine in the brain, a neurotransmitter involved in various cognitive processes such as memory formation and attention.
Age-Related Cognitive Decline: Meclofenoxate has been used to alleviate symptoms of age-related cognitive decline and dementia, including Alzheimer's disease. It may help improve cognitive function and slow the progression of cognitive decline in some individuals.
Neuroprotective Effects: Some research suggests that meclofenoxate may have neuroprotective properties, helping to protect brain cells from damage and promoting overall brain health.
ADHD and Attention Issues: Meclofenoxate has also been used off-label to manage symptoms of attention deficit hyperactivity disorder (ADHD) and other attention-related disorders, though evidence for its effectiveness in these conditions is limited.
Dosage and Administration: Meclofenoxate is typically taken orally in the form of tablets or capsules. The dosage and frequency of administration may vary depending on the individual's age, medical condition, and response to treatment. It is important to follow the prescribing healthcare provider's instructions and recommendations.
Side Effects: Common side effects of meclofenoxate may include gastrointestinal upset (such as nausea, vomiting, or diarrhea), headache, dizziness, and insomnia. These side effects are usually mild and transient.
Drug Interactions: Meclofenoxate may interact with other medications or supplements, particularly those affecting cholinergic activity or neurotransmitter levels in the brain. Patients should inform their healthcare provider about all medications and supplements they are taking to avoid potential interactions.
Contraindications: Meclofenoxate may not be suitable for individuals with certain medical conditions, such as epilepsy or severe cardiovascular disease. It is important to discuss any pre-existing medical conditions with a healthcare provider before starting treatment with meclofenoxate.
Pregnancy and Lactation: The safety of meclofenoxate use during pregnancy or breastfeeding has not been well studied. Pregnant or nursing women should consult their healthcare provider before using meclofenoxate.
Individual Response: Not everyone may experience the same effects from meclofenoxate, and individual responses to the medication can vary. Some individuals may notice significant improvements in cognitive function, while others may not experience noticeable benefits.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 2.4 | 0.3 | 7 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.1 | 4 |
| Allergic Rhinitis (Hay Fever) | 0.4 | 1.4 | -2.5 |
| Allergies | 3.2 | 0.9 | 2.56 |
| Allergy to milk products | 0.3 | 0.5 | -0.67 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 1.3 | 2.8 | -1.15 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.2 | 0.6 | 2.67 |
| Ankylosing spondylitis | 2 | 0.5 | 3 |
| Anorexia Nervosa | 0.1 | 1.1 | -10 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
| Asthma | 0.8 | 1 | -0.25 |
| Atherosclerosis | 0.5 | 0.9 | -0.8 |
| Atrial fibrillation | 1.9 | 0.6 | 2.17 |
| Autism | 3.9 | 4.8 | -0.23 |
| Barrett esophagus cancer | 0.4 | 0.4 | |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Bipolar Disorder | 0.3 | 0.9 | -2 |
| Brain Trauma | 0.5 | 0.4 | 0.25 |
| Carcinoma | 1.8 | 1.5 | 0.2 |
| Celiac Disease | 0.9 | 2.9 | -2.22 |
| Cerebral Palsy | 0.9 | 0.6 | 0.5 |
| Chronic Fatigue Syndrome | 2.4 | 2.7 | -0.13 |
| Chronic Kidney Disease | 0.6 | 1 | -0.67 |
| Chronic Lyme | 0.4 | -0.4 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.6 | -0.5 |
| Chronic Urticaria (Hives) | 0.7 | 0.5 | 0.4 |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.5 | -0.25 |
| Colorectal Cancer | 1.2 | 0.6 | 1 |
| Constipation | 0.6 | 0.5 | 0.2 |
| Coronary artery disease | 0.3 | 0.7 | -1.33 |
| COVID-19 | 6.6 | 6.5 | 0.02 |
| Crohn's Disease | 2.9 | 3.2 | -0.1 |
| cystic fibrosis | 0.3 | 0.6 | -1 |
| deep vein thrombosis | 0.3 | 0.2 | 0.5 |
| Depression | 4.9 | 3.9 | 0.26 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.5 | 0.3 | 0.67 |
| Endometriosis | 1.3 | 0.9 | 0.44 |
| Eosinophilic Esophagitis | 0.4 | -0.4 | |
| Epilepsy | 1.3 | 1.4 | -0.08 |
| Fibromyalgia | 1.3 | 0.5 | 1.6 |
| Functional constipation / chronic idiopathic constipation | 2.3 | 0.9 | 1.56 |
| gallstone disease (gsd) | 1.2 | 0.5 | 1.4 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 0.5 | -0.25 |
| Generalized anxiety disorder | 0.5 | 1.1 | -1.2 |
| giant cell arteritis | 0 | 0 | |
| Graves' disease | 0.8 | 1 | -0.25 |
| Halitosis | 0.5 | 0.5 | |
| Hashimoto's thyroiditis | 1.4 | 0.4 | 2.5 |
| Hidradenitis Suppurativa | 0.4 | -0.4 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.1 | 0.4 | 4.25 |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.4 | -1 |
| hyperglycemia | 0.1 | 1.4 | -13 |
| Hyperlipidemia (High Blood Fats) | 0.8 | 0.3 | 1.67 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.1 | 3 | -1.73 |
| Hypothyroidism | 0.8 | -0.8 | |
| Hypoxia | 0.5 | 0.5 | |
| IgA nephropathy (IgAN) | 1.7 | -1.7 | |
| Inflammatory Bowel Disease | 1.6 | 3.8 | -1.37 |
| Insomnia | 0.4 | 0.7 | -0.75 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.5 | 0.3 | 0.67 |
| Irritable Bowel Syndrome | 2.3 | 2.3 | 0 |
| Liver Cirrhosis | 2.2 | 1.6 | 0.38 |
| Long COVID | 3.7 | 5.3 | -0.43 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 0.3 | 1 | -2.33 |
| ME/CFS with IBS | 0.2 | 1.5 | -6.5 |
| ME/CFS without IBS | 1 | 1.4 | -0.4 |
| Menopause | 1.5 | 1.5 | |
| Metabolic Syndrome | 3.2 | 4.4 | -0.38 |
| Mood Disorders | 6.4 | 4.2 | 0.52 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.3 | 1 |
| Multiple Sclerosis | 3.1 | 1.7 | 0.82 |
| Multiple system atrophy (MSA) | 1.5 | 0.5 | 2 |
| Neuropathy (all types) | 0.5 | 0.1 | 4 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 3.5 | -2.89 |
| NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
| Obesity | 4.3 | 2.1 | 1.05 |
| obsessive-compulsive disorder | 2.7 | 1.6 | 0.69 |
| Osteoarthritis | 0.6 | 0.6 | |
| Osteoporosis | 0.9 | 0.8 | 0.13 |
| pancreatic cancer | 0.2 | 0.2 | |
| Parkinson's Disease | 1.8 | 1.5 | 0.2 |
| Polycystic ovary syndrome | 0.6 | 0.9 | -0.5 |
| Postural orthostatic tachycardia syndrome | 0 | 0.3 | 0 |
| Premenstrual dysphoric disorder | 0.8 | 0.1 | 7 |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Psoriasis | 2.4 | 1.1 | 1.18 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3 | 1.8 | 0.67 |
| Rosacea | 0.3 | 0.3 | 0 |
| Schizophrenia | 4.1 | 0.8 | 4.12 |
| scoliosis | 0.7 | -0.7 | |
| Sjögren syndrome | 1.9 | 1.6 | 0.19 |
| Sleep Apnea | 0.5 | 0.9 | -0.8 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.7 | -2.5 |
| Stress / posttraumatic stress disorder | 1.4 | 1.9 | -0.36 |
| Systemic Lupus Erythematosus | 1.5 | 1.3 | 0.15 |
| Tic Disorder | 0.2 | 0.8 | -3 |
| Tourette syndrome | 0.2 | 0.1 | 1 |
| Type 1 Diabetes | 1.3 | 1 | 0.3 |
| Type 2 Diabetes | 3.2 | 2.7 | 0.19 |
| Ulcerative colitis | 1.2 | 2 | -0.67 |
| Unhealthy Ageing | 1.5 | 1.1 | 0.36 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.